Condition
Cancer
Estimated Enrollment: 130
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Crossover Assignment|Masking: Double Blind (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
Study ID Numbers: INS-05-001|CDR0000581128
Study First Received: October 1, 2007
Last Updated: January 14, 2014
Estimated Primary Completion Date: February 2010
Primary Outcome Measures:
Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30)|Summed Pain Intensity Differences (SPID) at 5, 10, 15, 45, and 60 Minutes After Dosing|Total Pain Relief (TOTPAR) at 5, 10, 15, 30, 45, and 60 Minutes After Dosing|Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing
Sponsors and Collaborators:
INSYS Therapeutics Inc|National Cancer Institute (NCI)
Website Link: https://ClinicalTrials.gov/show/NCT00538850
